Key result
Alirocumab is linked to LDL-C goal achievement in ~69% of high-risk patients at one year.
Why the study?
Does alirocumab improve achievement of recommended LDL-C goals in Italian patients with elevated cholesterol at high or very-high cardiovascular risk?
Observational (n=797)
Yes
Does alirocumab improve achievement of recommended LDL-C goals in Italian patients with elevated cholesterol at high or very-high cardiovascular risk?
Answers are grounded in this paper and cite their sources.
Alirocumab is highly effective and well-tolerated in a real-world setting for achieving LDL-C goals in high-risk patients over long-term follow-up.
Background: The OMERO study (Observational Multicenter study on Effectiveness and tolerability of aliROcumab in real-world) aimed to evaluate the long-term effectiveness, safety and adherence of alirocumab in a cohort of Italian patients with elevated cholesterol at high- or very-high cardiovascular risk. Methods: Italian patients with elevated cholesterol received alirocumab for at least six months before the inclusion visit and were monitored for up to five years. The achievement of the recommended LDL-Cholesterol (LDL-C) goal (70 mg/dL in high-risk patients; 100 mg/dL in very-high-risk patients) after one year, regardless of modifications of concurrent lipid-lowering therapy or treatment adherence, was the primary endpoint of the study. The evaluation of the lipid profile, the concomitant use of lipid-lowering therapies, the treatment adherence and the occurrence of adverse events were also investigated. Results: 517 (68.6 %) of the 754 FAS patients met the primary endpoint 12 months after beginning their treatment with alirocumab. Median (mean ± SD) LDL-C reductions at the final visit (median or mean follow-up period) were -60.7 % (-57.4 % ± 19.3 %) compared to baseline. The primary endpoint was achieved by 341(70.7%) of the 482 patients with an LDL-C measurement 3 years after initiating alirocumab. Adherence to the alirocumab regimen was approximately 100 % during the observation period. Eighteen (2.3 %) of the 797 patients included in the safety population experienced at least one adverse drug reaction. Conclusion: The effectiveness of alirocumab in reducing LDL-C and its favorable safety and tolerability profile have been consistently confirmed in a real-world setting among Italian patients treated for up to 3 years.
No takes yet. Share an insight, caveat, or question.
Catapano et al. (2025) conducted an observational in Elevated cholesterol at high- or very-high cardiovascular risk (n=797). Alirocumab was evaluated on Achievement of the recommended LDL-Cholesterol (LDL-C) goal after one year. Alirocumab treatment enabled 68.6% of patients with elevated cholesterol at high- or very-high cardiovascular risk to achieve their recommended LDL-C goals at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: